cilostazol has been researched along with Fibrosis in 5 studies
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Excerpt | Relevance | Reference |
---|---|---|
"Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 7.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
"Cardiac fibrosis is characterized by the net accumulation of extracellular matrix in the myocardium and is an integral component of most pathological cardiac conditions." | 5.72 | Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice. ( Hada, Y; Uchida, HA; Umebayashi, R; Wada, J; Yoshida, M, 2022) |
"Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 3.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
"Cardiac fibrosis is characterized by the net accumulation of extracellular matrix in the myocardium and is an integral component of most pathological cardiac conditions." | 1.72 | Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice. ( Hada, Y; Uchida, HA; Umebayashi, R; Wada, J; Yoshida, M, 2022) |
"Cilostazol is an antiplatelet agent that can induce the regression of atherosclerosis." | 1.40 | Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy. ( Narumi, S; Ohba, H; Oura, K; Sasaki, M; Terayama, Y; Uwano, I; Yamaguchi Oura, M, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Hada, Y | 1 |
Uchida, HA | 1 |
Umebayashi, R | 1 |
Yoshida, M | 1 |
Wada, J | 1 |
Reddy, SS | 1 |
Agarwal, H | 1 |
Barthwal, MK | 1 |
Yamaguchi Oura, M | 1 |
Sasaki, M | 1 |
Ohba, H | 1 |
Narumi, S | 1 |
Oura, K | 1 |
Uwano, I | 1 |
Terayama, Y | 1 |
Koh, JS | 1 |
Yi, CO | 1 |
Heo, RW | 1 |
Ahn, JW | 1 |
Park, JR | 1 |
Lee, JE | 1 |
Kim, JH | 1 |
Hwang, JY | 1 |
Roh, GS | 1 |
Mendes, JB | 1 |
Campos, PP | 1 |
Rocha, MA | 1 |
Andrade, SP | 1 |
5 other studies available for cilostazol and Fibrosis
Article | Year |
---|---|
Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice.
Topics: Angiotensin II; Animals; Cilostazol; Fibrosis; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockou | 2022 |
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, A | 2018 |
Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy.
Topics: Aged; Carotid Artery Diseases; Cilostazol; Female; Fibrosis; Humans; Imaging, Three-Dimensional; Int | 2014 |
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Cardiomyopathies; Cilostazol; Doxorubicin; | 2015 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C | 2009 |